Market capitalization | $146.03m |
Enterprise Value | $26.21m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.06 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-94.21m |
Free Cash Flow (TTM) Free Cash Flow | $-82.77m |
Cash position | $138.86m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a PepGen forecast:
5 Analysts have issued a PepGen forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.48 -1.48 |
51%
51%
|
|
EBITDA | -93 -93 |
16%
16%
|
EBIT (Operating Income) EBIT | -94 -94 |
16%
16%
|
Net Profit | -87 -87 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Head office | United States |
CEO | James McArthur |
Employees | 64 |
Founded | 2018 |
Website | pepgen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.